~ Attachment I Zs
AUG 1 3 2004 $10(K) Summary K ol b2—
DuraLITE-GL
This 510(K) Summary of safety and effectiveness for the DuraLITE-GL .
is submitted in accordance with the requirements of the SMDA 1990 and following guidance concerning
the organization and content of a 510() summary.
Applicant: Laser Scientific
Address: Laser Scientific
115 Sundance Parkway #230B .
Round Rock, TX 78681
Contact Person: Mr. John Crownover ;
Telephone: 1-512-733-8709
Preparation Date: May 1, 2004
Device Trade Name: DuraLITE-GL
Common Name: Accessory to a Laser Device
Classification Name: Instrument, Surgical, Powered, laser
79-GEX, 21 CFR 878-48
: Legally Marketed Predicate Device: GentleLASE Plus Fiber Optic cleared under K024371, K024260,
K024335, K994260, K984601K003460
Description of the DuraLITE-GL The DuraLITE-GL is an exact replacement component for the
Candela GentleLASE Pius fiber optic.
Intended use of the DuraLITE-GL The DuraLite-GL is a replacernent fiber optic component for the
Candela GentleLASE family of lasers.
The DuraLite-GL may be used as a replacement part for all
procedures as cleared by the FDA for the Candela GentleLasc
family of lasers. : : / .
Performance Data: Physical, Optical, Connectivity and Environmental testing have
been performed. Testing validates that the performance of the
DurLite-GL I identical to the fiber optic components
manufactured by Candela for the GentleLaso family of lasers.
Results of Clinical Study: None
Canctusion: The DuraLITE-GL is substantially equivalent to other existing
fiber optics components in commercial distribution for use in
Dermatology and Plastic Surgery.
3-1

preg
i DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
AE Be
— Food and Drug Administration
- 9200 Corporate Boulevard
AUG 1 3 2004 Rockville MD 20850
Mr. John Crownover
General Manger
Laser Scientific
115 Sundance Parkway, #230B
Round Rock, Texas 78681
Re: K041262
Trade/Device Name: DuraLite-GL
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: May 1, 2004
Received: May 17, 2004
Dear Mr. Crownover:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal F ood, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You taay, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801): good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. John Crownover
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results ina classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

cet M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure

indications for Use
510(k) Number (if known):__K S@endige 04+ | 26 2-—
Device Name:  _DuraLite-GL__
Indications For Use:
The Dural.tte-GL is a replacement fiber optic component for the Candela
GentieLASE family of lasers.
The DuraLite-GL may be used as a replacement part for all procedures aa cleared
by the FDA for the Candela GentieLase family of lasers.

Prescription Use x AND/OR Over-The-Counter Use

(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
OSS

Concurrence of CORH, Office of Device Evaluation (ODE)
(Division Sign-Off) Page 1 of 1
Division of General, Restorative,
and Neurological Devices
510(k) Number 67/26 2%

